Company intelligence / Profile preview

Allegro Ophthalmics, LLC

San Juan Capistrano, California, United Statesallegroeye.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Risuteganib (Luminate®) met its primary endpoint in a Phase 2a clinical trial for intermediate dry AMD, with 48% of patients gaining ≥8 letters from baseline at week 28 compared to 7% in the sham group at week 12 (p=0.013). The company has received FDA agreement under Special Protocol Assessment (SPA) for its Phase 2b/3 clinical trial design. ALG-1007 for dry eye disease has completed a Phase 2 clinical trial outside the US.

Therapeutic areas: Ophthalmology
Modalities: Mitochondrial stabilizersIntegrin-regulating therapyOxidative stress stabilizers
Industry: Biotech

Drug pipeline

1 asset

risuteganib

Partnerships

Bausch Health

Beyond the preview

Go deeper on Allegro Ophthalmics, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allegro Ophthalmics, LLC.